Quarterly report pursuant to Section 13 or 15(d)

7. Stockholders' Equity (Details Narrative)

v3.10.0.1
7. Stockholders' Equity (Details Narrative) - USD ($)
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Proceeds from warrant exercises $ 1,480,000 $ 0
Warrants outstanding 3,152,225  
Warrants weighted average exercise price $ 4.33  
Pharmsynthez [Member]    
Debt converted, shares issued   125,397
Debt converted, amount converted   $ 500,000
Class B Warrants [Member]    
Warrants exercised 370,000  
Proceeds from warrant exercises $ 1,500,000  
Series B Preferred Stock [Member] | Common Stock [Member]    
Conversion of stock, shares converted 316,348 185,000
Conversion of stock, shares issued 316,348 185,000
Warrants [Member] | Common Stock [Member]    
Conversion of stock, shares issued 370,000